Protagonist Therapeutics, IncPTGX

時価総額

$52.9億

PER

ペプチド系バイオ医薬の新興企業。臨床開発中の治療候補とフェーズ3試験中心の研究開発、24年末時点で従業員126名（R&D98名）を展開。J&J系と武田とのライセンス協業、23年4月の公募で約1.08億ドル調達。米国・豪州で展開。

	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net income (loss)	-	-37	-39	-77	-66	-126	-127	-79	275
Stock-based compensation	2	4	7	8	8	16	24	29	38
Operating lease right-of-use asset amortization	-	-	-	-	-	2	2	2	2
Depreciation	0	0	1	1	1	1	1	1	1
Accretion of discount on marketable securities	-0	-1	-0	1	-0	-2	1	5	9
Other	-	-	-	-	-	-	-	0	-
Receivable from collaboration partner	-	2	3	2	-4	-1	-2	10	155
Prepaid expenses and other assets	2	0	-1	3	1	3	-4	-2	4
Research and development tax incentive receivable	-	-1	0	-1	1	2	-3	-	-
Accounts payable	-	-	-	-3	0	-1	2	-3	1
Payable to collaboration partner	-	-	1	0	1	-2	-1	-0	-0
Accrued expenses and other payables	3	5	2	1	6	19	-13	-6	4
Deferred revenue	-	-	-24	33	-27	-13	-2	-	31
Income taxes payable	-	-	-	-	-	-	-	-	3
Operating lease liability	-	-	-	-	-	2	3	3	2
Net cash provided by (used in) operating activities	-	4	-50	-42	-72	-108	-108	-70	184
Purchase of marketable securities	-	-	-	167	280	287	215	191	622
Proceeds from maturities of marketable securities	14	56	74	114	190	272	307	152	324
Purchases of property and equipment	0	1	0	1	0	1	1	1	1
Net cash (used in) provided by investing activities	-	16	2	-54	-91	-16	91	-39	-299
Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised	-	1	1	2	3	6	4	5	26
Tax withholding payments related to net settlement of restricted stock units	-	-	-	-	-	0	0	1	1
Proceeds from Issuance of Common Stock	-	-	2	34	213	124	-	108	-
Proceeds from Debt, Net of Issuance Costs	-	-	-	-	42	-	15	24	-
Proceeds from exercise of Warrants in exchange for issuance of Pre-Funded Warrants	-	-	-	-	-	-	-	34	-
Proceeds from Warrant Exercises	-	-	-	-	-	-	-	1	-
Issuance costs related to prior period common stock offering	-	-	-	-	-	-	0	-	-
Net cash provided by financing activities	-	66	24	46	248	130	19	170	26
Effect of exchange rate changes on cash, cash equivalents and restricted cash	-	0	-0	-0	0	-0	-0	-	-
Net (decrease) increase in cash, cash equivalents and restricted cash	-	85	-24	-49	84	6	2	61	-89
Cash paid for taxes	-	-	-	-	-	-	-	-	2
Right-of-use asset obtained in exchange for lease obligation	-	-	-	-	-	-	-	-	11
Leasehold Improvements Under Improvement Allowance	-	-	-	-	-	-	-	-	1
Capital Expenditures Incurred but Not yet Paid	0	-	0	0	0	0	0	0	0